Global Phase 1 Pharmacokinetic and Phase 3 Efficacy Assessments
First Public Phase 3 Results Among Keytruda Biosimilars Worldwide
"Clinical Trials Expected to Be Completed Within This Year"

Samsung Bioepis announced on June 29 that it has demonstrated equivalence to the original drug in both global Phase 1 and Phase 3 clinical trials of ‘SB27’, a biosimilar candidate of Keytruda.


Exterior view of the Samsung Bioepis building. Samsung Bioepis

Exterior view of the Samsung Bioepis building. Samsung Bioepis

View original image

The reference drug for SB27, Keytruda (ingredient name: pembrolizumab), is an immune-oncology therapy developed by MSD and is used to treat various cancers, including non-small cell lung cancer, melanoma, and head and neck cancer. With projected 2025 sales of USD 31.7 billion (approximately KRW 46 trillion), it is considered a global blockbuster drug.


Since 2024, Samsung Bioepis has been conducting global Phase 1 and Phase 3 trials simultaneously in patients with non-small cell lung cancer, comparing the pharmacokinetics, efficacy, safety, and immunogenicity of SB27 and Keytruda.


In the Phase 1 trial, conducted in four countries including Korea with 163 participants, pharmacokinetic equivalence was confirmed based on the area under the concentration-time curve (AUC), which evaluates the degree of drug exposure in the body.


Subsequently, in the Phase 3 trial with 555 participants across 14 countries, the primary endpoint was set as the objective response rate (ORR) at week 24. The results showed that SB27 demonstrated equivalent efficacy to the original drug. The safety and immunogenicity profiles were also similar between the two treatment groups. Samsung Bioepis explained that these results represent the first public disclosure of Phase 3 clinical data in the global Keytruda biosimilar development race.


Donghoon Shin, Vice President and Head of Clinical Development at Samsung Bioepis, stated, "By demonstrating equivalence between SB27 and the original drug, we have secured a significant achievement that showcases our global biosimilar development capabilities. We will continue our efforts to enhance treatment accessibility for patients in the immuno-oncology field through biosimilars."



Samsung Bioepis has adopted an overlap strategy by conducting Phase 1 and Phase 3 trials concurrently, accelerating the development timeline for SB27. The company plans to complete both trials within this year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing